Role of teneligliptin in rural India as add-on third drug in patients with type 2 diabetes mellitus
Keywords:DPP-4 inhibitor, Glycemic control, Teneligliptin, Type 2 diabetes mellitus
Background: Teneligliptin was introduced in India in May 2015. It has gained popularity and is already widely prescribed in type 2 diabetes mellitus (T2DM). The main aim of our study was to assess the efficacy and superiority of teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor as add-on third drug along with metformin and glimepiride in the treatment of type 2 diabetes mellitus in rural India.
Methods: In this comparative observational study, three groups of uncontrolled type 2 diabetes (on monotherapy) patients each comprising 50 in number were studied for 3 months. Groups were divided into patients on triple drug regimens (Group A- Metformin+Glimepiride+voglibose; Group B- Metformin+Glimepiride+Pioglitazone and Group C- Metformin+Glimepiride+Teneligliptin). In each group FBS and PPBS were tested at the beginning and at 4 weeks intervals. HbA1c was tested at the start of study and at the end of 12 weeks.
Results: After 12 weeks of therapy, it was observed that FBS, PPBS and HbA1c were significantly reduced in Group-C patients containing teneligliptin in comparison to Group-A and B containing voglibose and pioglitazone respectively.Conclusions: Teneligliptin significantly improves glycemic control in Indian patients with T2DM when prescribed as an add-on to one or more other commonly prescribed antidiabetic drugs, even in patients of rural India. It may be an ideal add-on third drug in the treatment of T2 DM patients.
International diabetes federation. IDF Diabetes Atlas, 7th ed. Brussels, Belgium: International Diabetes Federation, 2015. Available from: http://www.diabetesatlas.org. Accessed Jan 27, 2017.
Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S. Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT- INDIA Study). Diabetes Metab Syndr Obes. 2016;9:347-53.
Munjal YP. API textbook of Medicine. 9th Ed. Association of Physicians of India; 341.
Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6.
Maladkar M, Sankar S, Kamat K. Teneligliptin: Heralding change in type 2 Diabetes. J Diabetes Mellitus. 2016;6(2):113-31.
Scott LJ. Teneligliptin; a review in type 2 diabetes. Clin Drug Investig. 2015;35(11);765-72.
Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Dia Obes Metab. 2016;18(4):333-47.
Foroutan N, Muratov S, Levine M. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs Sulfonylurea in metformin–based combination therapy for type-2 diabetes mellitus: Systematic review and metaanalysis. Clin Invest Med. 2016;39(2):E48-62.
Fauci K, Longo H, Loscalzo J. Harrison’s principles of internal medicine 19th Ed. 2015;2:2415.
Scheen AJ. A Review of Gliptins in 2011. Expert Opinion on Pharmacotherapy. 2012;13:81-99.
Morishita R, Norkagami H, Teneligliptin: Expectations for its pleiotropic action. Expert Opin Pharmacother. 2015;16(3):417-26.
Chandalia HB. RSSDI Text book of diabetes mellitus 3rd Ed. Jaypee Digital; 2014:552.
Mathieu C, Barnett AH, Brath H. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013;67(10):947-56.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
Saglietti G, Placentino G, Schellino A. Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy. Clin Drug Investig. 2014;34(7):513-9.
Kubota A, Maeda H, Kanamori A. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig. 2012;3(6):503-9.
Yadav D, Mishra M, Tiwari A, Bisen PS, Goswamy HM, Prasad GB. Prevalence of dyslipidemia and hypertension in Indian type 2 diabetic patients with metabolic syndrome and its clinical significance. Osong Public Health Res Perspect. 2014;5(3):169-75.